<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735030</url>
  </required_header>
  <id_info>
    <org_study_id>18CH-hCG09</org_study_id>
    <nct_id>NCT03735030</nct_id>
  </id_info>
  <brief_title>Comparative Bioavailability Study of Human Chorionic Gonadotropin (hCG)-IBSA Versus a Marketed hCG Formulation</brief_title>
  <official_title>Comparative Bioavailability Study of Choriomon® (IBSA) Versus a Marketed hCG Formulation, Following Subcutaneous Administration in Healthy Women. Single-dose, Open-label, Randomized, Two-period, Two-way Cross-over, Bioavailability Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study, the rate and extent of hCG absorption will be compared between the two
      treatments in healthy women aged 20 to 45 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Actual">August 2, 2019</completion_date>
  <primary_completion_date type="Actual">August 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of absorption (Cmax)</measure>
    <time_frame>192 hours post dose</time_frame>
    <description>To assess the bioavailability of the test and reference products in terms of rate (baseline-corrected, dose-normalised Cmax) of hCG absorption after single s.c. injection to healthy female subjects.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Extent of absorption (AUC0-t), Area under the concentration-time curve</measure>
    <time_frame>192 hours post dose</time_frame>
    <description>To assess the bioavailability of the test and reference products in terms of extent (baseline-corrected, dose-normalised AUC0-t) of hCG absorption after single s.c. injection to healthy female subjects.Area under the concentration-time curve from administration to the last observed concentration time t, calculated with the linear trapezoidal method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>t1/2: Half-life</measure>
    <time_frame>192 hours post dose</time_frame>
    <description>To evaluate the baseline-corrected, dose-normalised (when applicable) t1/2 (Half-life) value after single dose administration of test and reference products;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to achieve Cmax</measure>
    <time_frame>192 hours post dose</time_frame>
    <description>To evaluate the baseline-corrected, dose-normalised (when applicable) Tmax value after single dose administration of test and reference products;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞: Area under the concentration-time curve extrapolated to infinity</measure>
    <time_frame>192 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frel : Relative bioavailability</measure>
    <time_frame>192 hours post dose</time_frame>
    <description>calculated as dose-normalised ratio AUC0-t (T)/dose(T) / AUC0-t (R)/dose(R)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment emergent adverse events (TEAEs)</measure>
    <time_frame>through study completion up to 46 days.</time_frame>
    <description>percentage of subjects with any TEAE</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>human hCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>recombinant hCG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human hCG 10'000 IU</intervention_name>
    <description>A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.</description>
    <arm_group_label>human hCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant hCG 6'500 IU</intervention_name>
    <description>A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.</description>
    <arm_group_label>recombinant hCG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent: signed written informed consent before inclusion in the study;

          2. Sex and Age: healthy pre-menopausal women, 20-45 years old inclusive;

          3. Body Mass Index: 18.5-30 kg/m2 inclusive;

          4. Vital signs: systolic blood pressure 100-139 mmHg, diastolic blood pressure 50-89
             mmHg, heart rate 50-90 bpm, measured after 5 min at rest in the sitting position;

          5. Hormonal oral contraceptives: Combined oral contraceptive pill for at least 2 months
             before the screening visit;

          6. Menstrual cycle: history of a normal menstrual cycle before combined oral
             contraceptive pill use;

          7. hCG: endogenous hCG levels &lt;1.2 IU/L at screening and Day -1, Period 1;

          8. Pituitary down-regulation: Luteinizing hormone (LH) &lt;5 IU/L; Follicle stimulating
             hormone (FSH) &lt;4 IU/L at Day -1, Period 1;

          9. Papanicolaou smear (PAP) test: negative or not clinically significant PAP test results
             within 12 months before the screening visit or at screening;

         10. Full comprehension: ability to comprehend the full nature and purpose of the study,
             including possible risks and side effects; ability to co-operate with the investigator
             and to comply with the requirements of the entire study;

         11. Additional contraception: study participants with an active sexual life must be using
             one additional contraceptive method, as follows:

               1. A male sexual partner who agrees to use a male condom with spermicide

               2. A sterile sexual partner.

        Exclusion Criteria:

          1. Contraindications: any contraindications to combined oral contraceptive pill or
             gonadotropins;

          2. Electrocardiogram 12-leads (supine position): clinically significant abnormalities;

          3. Physical findings: clinically significant abnormal physical findings which could
             interfere with the objectives of the study;

          4. Laboratory analyses: clinically significant abnormal laboratory values indicative of
             physical illness;

          5. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or
             formulations' ingredients; history of anaphylaxis to drugs or allergic reactions in
             general, which the investigator considers may affect the outcome of the study;

          6. Diseases: relevant history of cardiovascular, pulmonary, hepatic, renal,
             haematological, gastrointestinal, immunological, dermatological, endocrine,
             genitourinary (e.g. polycystic ovary disease, ovarian cysts, primary ovarian failure,
             early menopause or abnormal bleeding of undetermined origin), malignant neoplasia,
             neurological or psychiatric diseases that could interfere with the aim of the study;

          7. Medications: treatment with gonadotropin preparations within 6 months prior to
             screening; other medications, including over the counter medications and herbal
             remedies, for 2 weeks before the start of the study;

          8. Investigative drug studies: participation in the evaluation of any investigational
             product for 3 months before this study. The 3-month interval is calculated as the time
             between the first calendar day of the month that follows the last visit of the
             previous study and the first day of the present study;

          9. Blood donation: blood donations for 3 months before this study;

         10. Drug, alcohol, caffeine, tobacco: history of drug, alcohol (&gt;1 drink/day defined
             according to the United Stated Department of Agriculture (USDA) Dietary Guidelines
             2015-2020; 17), caffeine (&gt;5 cups coffee/tea/day) or tobacco abuse (≥10
             cigarettes/day);

         11. Drug test: positive result at the drug test at screening or day -1, Period 1;

         12. Alcohol test: positive alcohol breath test on day -1;

         13. Diet: abnormal diets (&lt;1600 or &gt;3500 kcal/day) or substantial changes in eating habits
             in the 4 weeks before this study; vegetarians;

         14. Pregnancy: positive or missing pregnancy test at screening or at day -1 of each
             period; pregnant or lactating women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CROSS Research SA</name>
      <address>
        <city>Arzo</city>
        <state>Ticino</state>
        <zip>6864</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>October 31, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

